Tumor Necrosis Factor Alfa Antagonists for Pediatric Immune-Mediated Diseases

Marcia L. Buck, Pharm.D., FCCP

Pediatr Pharm. 2007;13(8):1-4. 

In This Article

Mechanism of Action

Tumor necrosis factor (TNF) is a pro-inflammatory cytokine produced by T lymphocytes and macrophages. Its primary role in healthy individuals is to control infection by intracellular pathogens. In patients with immune-mediated diseases, TNFα levels are consistently elevated, leading to an abnormal sustained inflammatory response. The TNFα antagonists are monoclonal antibodies that bind to TNFα, forming a complex which inhibits its ability to bind to cell surface TNF receptors. Blocking TNFα activity prevents induction of proinflammatory cytokines, including interleukins (IL-1 and IL-6), as well as inhibiting expression of adhesion molecules responsible for leukocyte migration, activation of neutrophil and eosinophil functional activity, and induction of acute phase reactants.[2,3,4,5,6,7,8]

Infliximab is a chimeric monoclonal antibody, with a mouse variable region and a human constant region, that binds both soluble and transmembrane TNFα receptors. It does not bind TNFβ. Etanercept is a fully human, soluble fusion protein. It is formed from the linkage of two ligand-bearing regions of the p75 TNF receptor and the Fc portion of human IgG1. It binds both TNFα (soluble form only) and TNFβ. Adalimumab is a fully human monoclonal antibody to TNFα, produced by recombinant DNA technology. It does not bind to TNFβ.[3,4,5]


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: